Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in inoperable chronic thromboembolic pulmonary hypertension
NL-OMON40399Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Ambrisentan with Placebo (2 arms). Primary endpoint: Change from baseline in 6-minute walk test at week 16. Started Mar 2014; status: active, not recruiting.
02
Drugs
ambrisentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NL-OMON40399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40399.